Physician profile
Robert A Desantis
NPI 1053350223
$212,486.03
in general payments reported to CMS, 2019-2025
18 companies · $29K in 2025
The $29K reported for 2025 was more than what 99% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $32K · 2021: $28K · 2022: $33K · 2023: $45K · 2024: $23K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $44K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $38K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,500 · Travel and Lodging: $4,539 · Food and Beverage: $3,613 · Gift: $22.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $44,019.27 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $37,575.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,500.00 |
| Travel and Lodging | $4,538.93 |
| Food and Beverage | $3,613.08 |
| Gift | $22.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $123,282.71 | 2019-2025 | Da Vinci Surgical System, Da Vinci Sp |
| Organon LLC | $77,559.90 | 2021-2025 | Nexplanon |
| Merck Sharp & Dohme LLC | $9,648.19 | 2019-2021 | |
| Myovant Sciences INC. | $1,052.62 | 2021 | |
| Abbvie INC. | $342.39 | 2019-2022 | |
| Hologic Sales and Service, LLC | $83.10 | 2023-2025 | Novasure, Coolseal Generator, Myosure Tissue Removal Device |
| Coopersurgical, INC. | $76.56 | 2021 | |
| Pfizer INC. | $65.10 | 2025 | |
| Novo Nordisk INC | $64.32 | 2023-2024 | Wegovy, Saxenda |
| Medtronic, INC. | $60.67 | 2024 | Ligasure, Truclear |
| Astellas Pharma US INC | $58.57 | 2023-2024 | Veozah |
| Mayne Pharma Commercial LLC | $56.73 | 2023-2025 | |
| Coloplast Corp | $41.86 | 2019-2020 | |
| Therapeuticsmd, INC. | $28.62 | 2019 | |
| Sumitomo Pharma America, INC. | $19.27 | 2023 | Myfembree |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $18.62 | 2025 | Intrarosa, Femlyv |
| Acella Pharmaceuticals, LLC | $13.53 | 2024 | NP Thyroid 60 |
| Evofem Biosciences, INC. | $13.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Desantis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.